Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 50 of 144

    1.

    Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of cyclin E.

    Vredeveld LC, Rowland BD, Douma S, Bernards R, Peeper DS.

    Carcinogenesis. 2009 Nov 25. [Epub ahead of print]PMID: 19942610 [PubMed - as supplied by publisher]Related articles

    2.

    UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid.

    Epping MT, Meijer LA, Bos JL, Bernards R.

    Mol Cancer Res. 2009 Nov;7(11):1861-70. Epub 2009 Oct 20.PMID: 19843631 [PubMed - in process]Related articles

    3.

    Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.

    Mullenders J, Bernards R.

    Oncogene. 2009 Sep 21. [Epub ahead of print]PMID: 19767776 [PubMed - as supplied by publisher]Related articles

    4.

    Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen.

    Mullenders J, von der Saal W, van Dongen MM, Reiff U, van Willigen R, Beijersbergen RL, Tiefenthaler G, Klein C, Bernards R.

    Clin Cancer Res. 2009 Sep 15;15(18):5811-9. Epub 2009 Sep 1.PMID: 19723642 [PubMed - in process]Related articles

    5.

    ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome.

    Huang S, Laoukili J, Epping MT, Koster J, Hölzel M, Westerman BA, Nijkamp W, Hata A, Asgharzadeh S, Seeger RC, Versteeg R, Beijersbergen RL, Bernards R.

    Cancer Cell. 2009 Apr 7;15(4):328-40.PMID: 19345331 [PubMed - indexed for MEDLINE]Related articles

    6.

    A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway.

    Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL.

    PLoS One. 2009;4(3):e4798. Epub 2009 Mar 11.PMID: 19277210 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.

    Fotheringham S, Epping MT, Stimson L, Khan O, Wood V, Pezzella F, Bernards R, La Thangue NB.

    Cancer Cell. 2009 Jan 6;15(1):57-66.PMID: 19111881 [PubMed - indexed for MEDLINE]Related articles

    8.

    RNAi Delivers Insights into Liver Cancer.

    Bernards R.

    Cell. 2008 Nov 28;135(5):793-5.PMID: 19041743 [PubMed - indexed for MEDLINE]Related articles

    9.

    Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

    Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J.

    Cancer Res. 2008 Nov 15;68(22):9221-30.PMID: 19010894 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1.

    Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, Bernards R, Eilers M.

    EMBO J. 2008 Nov 5;27(21):2851-61. Epub 2008 Oct 16.PMID: 18923429 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Cancer: Entangled pathways.

    Bernards R.

    Nature. 2008 Sep 25;455(7212):479-80. No abstract available. PMID: 18818647 [PubMed - indexed for MEDLINE]Related articles

    12.

    Are short-term or long-term recurrence rates more important in breast cancer screening?

    Rutgers EJ, Pusztai L, Bernards R.

    Ann Intern Med. 2008 Sep 2;149(5):357; author reply 357-8. No abstract available. PMID: 18765708 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.

    Epping MT, Bernards R.

    Int J Biochem Cell Biol. 2009 Jan;41(1):16-20. Epub 2008 Aug 12. Review.PMID: 18765293 [PubMed - indexed for MEDLINE]Related articles

    14.

    Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling.

    Kortlever RM, Brummelkamp TR, van Meeteren LA, Moolenaar WH, Bernards R.

    Mol Cancer Res. 2008 Sep;6(9):1452-60. Epub 2008 Aug 22.PMID: 18723828 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

    Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT.

    Cancer Res. 2008 Aug 1;68(15):6084-91.PMID: 18676830 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    PRAME expression and clinical outcome of breast cancer.

    Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R.

    Br J Cancer. 2008 Aug 5;99(3):398-403. Epub 2008 Jul 22.PMID: 18648365 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity.

    Kortlever RM, Nijwening JH, Bernards R.

    J Biol Chem. 2008 Sep 5;283(36):24308-13. Epub 2008 Jul 9.PMID: 18614541 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Protein phosphatase 2A regulatory subunits and cancer.

    Eichhorn PJ, Creyghton MP, Bernards R.

    Biochim Biophys Acta. 2009 Jan;1795(1):1-15. Epub 2008 Jun 3. Review.PMID: 18588945 [PubMed - indexed for MEDLINE]Related articles

    19.

    Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.

    Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S.

    Clin Cancer Res. 2008 May 15;14(10):2988-93.PMID: 18483364 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Reaction to American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

    Bernards R.

    J Clin Oncol. 2008 Apr 20;26(12):2057-8; author reply 2060-1. No abstract available. PMID: 18421062 [PubMed - indexed for MEDLINE]Related articles

    21.

    Enabling personalized cancer medicine through analysis of gene-expression patterns.

    van't Veer LJ, Bernards R.

    Nature. 2008 Apr 3;452(7187):564-70. Review.PMID: 18385730 [PubMed - indexed for MEDLINE]Related articles

    22.

    A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC.

    Eichhorn PJ, Creyghton MP, Wilhelmsen K, van Dam H, Bernards R.

    PLoS Genet. 2007 Dec;3(12):e218.PMID: 18069897 [PubMed - indexed for MEDLINE]Related articlesFree article

    23.

    A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors.

    Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, Bernards R.

    Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17777-82. Epub 2007 Oct 29.PMID: 17968018 [PubMed - indexed for MEDLINE]Related articlesFree article

    24.

    A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

    Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R.

    Cancer Cell. 2007 Oct;12(4):395-402.PMID: 17936563 [PubMed - indexed for MEDLINE]Related articles

    25.

    The ubiquitin-specific protease USP28 is required for MYC stability.

    Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, Moll R, Elledge SJ, Eilers M.

    Nat Cell Biol. 2007 Jul;9(7):765-74. Epub 2007 Jun 10.PMID: 17558397 [PubMed - indexed for MEDLINE]Related articles

    26.

    [The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference]

    Bernards R.

    Ned Tijdschr Geneeskd. 2006 Dec 30;150(52):2849-53. Dutch. PMID: 17319214 [PubMed - indexed for MEDLINE]Related articles

    27.

    Senescence, wound healing and cancer: the PAI-1 connection.

    Kortlever RM, Bernards R.

    Cell Cycle. 2006 Dec;5(23):2697-703. Epub 2006 Dec 1.PMID: 17172853 [PubMed - indexed for MEDLINE]Related articles

    28.

    Exploring the uses of RNAi--gene knockdown and the Nobel Prize.

    Bernards R.

    N Engl J Med. 2006 Dec 7;355(23):2391-3. No abstract available. PMID: 17151363 [PubMed - indexed for MEDLINE]Related articles

    29.

    Re-evaluating cell-cycle regulation by E2Fs.

    Rowland BD, Bernards R.

    Cell. 2006 Dec 1;127(5):871-4.PMID: 17129771 [PubMed - indexed for MEDLINE]Related articles

    30.

    A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.

    Epping MT, Bernards R.

    Cancer Res. 2006 Nov 15;66(22):10639-42. Review.PMID: 17108098 [PubMed - indexed for MEDLINE]Related articlesFree article

    31.

    Converting a breast cancer microarray signature into a high-throughput diagnostic test.

    Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF, Van't Veer LJ.

    BMC Genomics. 2006 Oct 30;7:278.PMID: 17074082 [PubMed - indexed for MEDLINE]Related articlesFree article

    32.

    Minimizing the risk of reporting false positives in large-scale RNAi screens.

    Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, Downward J, Ellenberg J, Fraser AG, Hacohen N, Hahn WC, Jackson AL, Kiger A, Linsley PS, Lum L, Ma Y, Mathey-Prévôt B, Root DE, Sabatini DM, Taipale J, Perrimon N, Bernards R.

    Nat Methods. 2006 Oct;3(10):777-9.PMID: 16990807 [PubMed - indexed for MEDLINE]Related articles

    33.

    shRNA libraries and their use in cancer genetics.

    Bernards R, Brummelkamp TR, Beijersbergen RL.

    Nat Methods. 2006 Sep;3(9):701-6. Review.PMID: 16929315 [PubMed - indexed for MEDLINE]Related articles

    34.

    Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence.

    Kortlever RM, Higgins PJ, Bernards R.

    Nat Cell Biol. 2006 Aug;8(8):877-84. Epub 2006 Jul 23.PMID: 16862142 [PubMed - indexed for MEDLINE]Related articles

    35.

    An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis.

    Oosterkamp HM, Neering H, Nijman SM, Dirac AM, Mooi WJ, Bernards R, Brummelkamp TR.

    Br J Dermatol. 2006 Jul;155(1):182-5.PMID: 16792771 [PubMed - indexed for MEDLINE]Related articles

    36.

    A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta.

    Nijman SM, Hijmans EM, El Messaoudi S, van Dongen MM, Sardet C, Bernards R.

    J Biol Chem. 2006 Aug 4;281(31):21582-7. Epub 2006 May 31.PMID: 16737956 [PubMed - indexed for MEDLINE]Related articlesFree article

    37.

    PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle.

    Creyghton MP, Roël G, Eichhorn PJ, Vredeveld LC, Destrée O, Bernards R.

    Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5397-402. Epub 2006 Mar 27.PMID: 16567647 [PubMed - indexed for MEDLINE]Related articlesFree article

    38.

    Regulation of monoubiquitinated PCNA by DUB autocleavage.

    Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R, D'Andrea AD.

    Nat Cell Biol. 2006 Apr;8(4):339-47. Epub 2006 Mar 12.PMID: 16531995 [PubMed - indexed for MEDLINE]Related articles

    39.

    An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.

    Brummelkamp TR, Fabius AW, Mullenders J, Madiredjo M, Velds A, Kerkhoven RM, Bernards R, Beijersbergen RL.

    Nat Chem Biol. 2006 Apr;2(4):202-6. Epub 2006 Feb 13.PMID: 16474381 [PubMed - indexed for MEDLINE]Related articles

    40.

    A functionally distinct member of the DP family of E2F subunits.

    Milton A, Luoto K, Ingram L, Munro S, Logan N, Graham AL, Brummelkamp TR, Hijmans EM, Bernards R, La Thangue NB.

    Oncogene. 2006 May 25;25(22):3212-8.PMID: 16418725 [PubMed - indexed for MEDLINE]Related articles

    41.

    Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells.

    Nicke B, Bastien J, Khanna SJ, Warne PH, Cowling V, Cook SJ, Peters G, Delpuech O, Schulze A, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Ganesan TS, Downward J, Hancock DC.

    Mol Cell. 2005 Dec 9;20(5):673-85.PMID: 16337592 [PubMed - indexed for MEDLINE]Related articles

    42.

    A genomic and functional inventory of deubiquitinating enzymes.

    Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R.

    Cell. 2005 Dec 2;123(5):773-86. Review.PMID: 16325574 [PubMed - indexed for MEDLINE]Related articles

    43.

    Functional annotation of deubiquitinating enzymes using RNA interference.

    Dirac AM, Nijman SM, Brummelkamp TR, Bernards R.

    Methods Enzymol. 2005;398:554-67.PMID: 16275358 [PubMed - indexed for MEDLINE]Related articles

    44.

    The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene.

    Rowland BD, Bernards R, Peeper DS.

    Nat Cell Biol. 2005 Nov;7(11):1074-82.PMID: 16244670 [PubMed - indexed for MEDLINE]Related articles

    45.

    The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.

    Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R.

    Cell. 2005 Sep 23;122(6):835-47.PMID: 16179254 [PubMed - indexed for MEDLINE]Related articles

    46.

    Functional identification of cancer-relevant genes through large-scale RNA interference screens in mammalian cells.

    Brummelkamp TR, Berns K, Hijmans EM, Mullenders J, Fabius A, Heimerikx M, Velds A, Kerkhoven RM, Madiredjo M, Bernards R, Beijersbergen RL.

    Cold Spring Harb Symp Quant Biol. 2004;69:439-45. No abstract available. PMID: 16117679 [PubMed - indexed for MEDLINE]Related articles

    47.

    A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity.

    Kolfschoten IG, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM, Agami R.

    Cell. 2005 Jun 17;121(6):849-58.PMID: 15960973 [PubMed - indexed for MEDLINE]Related articles

    48.

    A functional approach to questions about life, death, and phosphorylation.

    Bernards R.

    Cancer Cell. 2005 Jun;7(6):503-4.PMID: 15950899 [PubMed - indexed for MEDLINE]Related articles

    49.

    A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.

    Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, Stoughton R, Friend S.

    Cancer Res. 2005 May 15;65(10):4059-66.PMID: 15899795 [PubMed - indexed for MEDLINE]Related articlesFree article

    50.

    The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway.

    Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R.

    Mol Cell. 2005 Feb 4;17(3):331-9.PMID: 15694335 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Find related data

    Search details

    » See more...